Represents approximately US$500,000 in potential minimum purchases over the initial term and targets growing demand for medication temperature protection across insulin, GLP-1 therapies, biologics and other injectable medications
Toronto, Ontario--(Newsfile Corp. - October 15, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (OTCQB:...
More...






